Clinical Trials Logo

Gastroesophageal Reflux clinical trials

View clinical trials related to Gastroesophageal Reflux.

Filter by:

NCT ID: NCT05937204 Not yet recruiting - Clinical trials for Gastroesophageal Reflux Disease

Nursing Teaching Scheme for Patients With Gastroesophageal Reflux Disease

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

The aims of the study are: - Assess patient's level of knowledge regarding gastroesophageal reflux disease. - Assess patient' compliance and symptoms of gastroesophageal reflux disease. - Design and implement nursing teaching scheme for patients with gastroesophageal reflux disease. - Evaluate the effect of nursing teaching scheme on patient' compliance and symptoms of gastroesophageal reflux disease.

NCT ID: NCT05900687 Not yet recruiting - Clinical trials for Gastroesophageal Reflux

Developing and Testing Mobile Health Question Prompt List in Gastroesophageal Reflux Disease

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

More than 40% of patients with gastroesophageal reflux disease (GERD) experience uncontrolled, chronic symptoms. This proposal aims to improve symptom control for patients with GERD, by developing a mobile health (mHealth) Question Prompt List (QPL) intervention that helps patient ask questions with his/her physician about GERD. The first aim is to gather feedback about daily challenges of living with GERD. The second aim is to gather feedback on the prototype app. The third (primary) aim of this project is to develop the mHealth application and measure differences in patient activation when used compared to standard of care.

NCT ID: NCT05899842 Recruiting - Clinical trials for Esophageal Achalasia

Routine Versus Symptomatic Protein Pump Inhibitor Therapy for Prevention of Gastroesophageal Reflux After Per Oral Endoscopic Myotomy for Esophageal Achalasia

IPPOEM
Start date: June 1, 2023
Phase: N/A
Study type: Interventional

Per Oral Endoscopic Myotomy (POEM) is a treatment of choice for achalasia with an excellent safety and efficacy profile. There is a high rate of esophagitis related to gastroesophageal reflux following this procedure. There is no recommendation on the prescription of protein pump inhibitors (PPI) after the procedure and no study has studied the benefit of systematic prescription of PPI after POEM for achalasia. The study authors hypothesize that routine PPI prescribing post-POEM for 12 months would reduce the rate of esophageal acid exposure compared to a symptom-based prescribing strategy.

NCT ID: NCT05899491 Recruiting - GERD Clinical Trials

Role of ARMA in Selective Subset of Refractory GERD Patients.

Start date: March 30, 2023
Phase: N/A
Study type: Interventional

To study the role of a novel endoscopic treatment technique (ARMA) in GERD patients who doesn't respond to PPI therapy (Proton Pump Inhibitor).

NCT ID: NCT05890001 Enrolling by invitation - Erosive Esophagitis Clinical Trials

A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease

Start date: April 5, 2023
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the safety of up to 12 months (52 weeks) of once daily oral administration of BLI5100 in patients with non-erosive reflux disease (NERD) or healed erosive esophagitis (EE).

NCT ID: NCT05886933 Active, not recruiting - Clinical trials for Gastroesophageal Reflux Disease

Study to Evaluate the Efficacy and Safety of FEXUCLUE Tablet

Start date: May 22, 2023
Phase:
Study type: Observational

This observational study is a large-scale, prospective, and multi-institutional observational study. Patients from 19 to 75 years of age, will take a self-assessment (PRO) during the study period before and after administration of Pexuclue tablet.

NCT ID: NCT05874726 Recruiting - Obesity Clinical Trials

Biological Sample Repository for Gastrointestinal Disorders

Start date: July 19, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study has the purpose of collecting biological samples from obese patients undergoing evaluation for weight loss by means of medical or endoscopic therapies; and of post bariatric surgery patients presenting with short- and long-term surgical complications. The aim is to enhance the overall understanding of the mechanisms leading to obesity, weight loss, failure to lose weight, and weight regain following treatment. Additional goals are to determine the efficacy of endoscopic and surgical procedures, to identify potential therapeutic targets and disease biomarkers that predict response to therapy.

NCT ID: NCT05871398 Completed - Clinical trials for Laryngopharyngeal Reflux Disease

The Efficacy of Potassium-competitive Acid Blocker in Patients With Laryngopharyngeal Reflux Disease

Start date: October 1, 2019
Phase: Phase 3
Study type: Interventional

Background/Aims: Tegoprazan is a novel potassium-competitive acid blocker that has a fast onset of action and can control gastric pH for a prolonged period, which could offer clinical benefit in acid-related disorders. The investigators aimed to evaluate whether tegoprazan would be more effective in controlling symptoms than placebo in patients with laryngopharyngeal reflux disease (LPRD). Methods: This double-blind, randomized, placebo-controlled trial randomly assigned 35 patients suffering LPRD symptom to two groups: Tegoprazan50mg once daily and placebo. The primary end point was complete resolution rate of LPRD symptoms after 8-week medication, and the secondary endpoints were complete resolution rate of LPRD symptoms after 4-week medication, change of reflux symptom index (RSI) and reflux finding score (RFS) from baseline at 4- and 8-week medication.

NCT ID: NCT05870163 Recruiting - Clinical trials for Gastroesophageal Reflux Disease (GERD)

Post-Market Registry for the Evaluation of RefluxStop in GERD Treatment

Start date: February 20, 2023
Phase:
Study type: Observational [Patient Registry]

This post-market registry aims to assess safety and performance of RefluxStop™ in the treatment of Gastroesophageal Reflux Disease (GERD) in standard of care procedures.

NCT ID: NCT05851482 Completed - Clinical trials for Gastro Esophageal Reflux

Validation of HRM Score for the GERD Diagnosis

HRM nomogram
Start date: December 1, 2022
Phase: N/A
Study type: Interventional

The goal of this prospective study is to validate a high resolution manometry score to predict pathologic GERD in patients with reflux symptoms. The main question it aims to answer is: Is it possible to predict GERD on high resolution manometry? Participants will be asked to undergo high resolution manometry and pH-study